Pemvidutide and survodutide are both investigational peptides that activate the glucagon and GLP-1 receptors together rather than targeting GLP-1 alone, placing them in the same mechanistic class. Neither is FDA-approved. Beyond that shared mechanism, though, the two programs differ in sponsor, lead indication, and stage of development.
Who Makes Them
Survodutide is being developed by Boehringer Ingelheim in partnership with Zealand Pharma, and is further along in the development pipeline, with Phase 3 trials underway for obesity, as covered in this site's dedicated survodutide guide. Pemvidutide is being developed independently by Altimmune and has not yet entered Phase 3 testing; the company reported reaching FDA alignment on Phase 3 trial design for a liver-disease indication in December 2025, with a Phase 3 program planned to begin in 2026.
Lead Indication: Where the Two Programs Diverge Most
This is the clearest point of difference. Survodutide's most advanced clinical program targets obesity and weight management, positioning it as a more direct competitor to drugs like semaglutide and tirzepatide. Pemvidutide's most advanced program instead targets metabolic dysfunction-associated steatohepatitis (MASH), a liver disease, with weight loss showing up as a secondary effect in that trial population rather than the primary goal. Pemvidutide is also being studied separately for alcohol use disorder, an indication survodutide's public trial program does not currently pursue.
Receptor Balance
Both drugs activate glucagon and GLP-1 receptors, but published mechanistic profiles describe somewhat different balances between the two: pemvidutide has been characterized by Altimmune as close to a 1:1 balanced ratio, while dual agonists in this broader class, survodutide included, can differ in relative receptor potency depending on their specific design. The practical significance of small differences in receptor balance for real-world outcomes like weight loss magnitude or liver-fat reduction isn't yet settled by head-to-head human data, since the two drugs haven't been tested directly against each other.
What the Efficacy Data Shows (in Their Own Trials)
In pemvidutide's Phase 2b IMPACT trial for MASH, the 1.8 mg dose produced a 54.7% reduction in liver fat content and 7.5% average weight loss over 48 weeks, alongside significant improvements in liver stiffness and fibrosis markers, compared to placebo. Survodutide's obesity-focused Phase 2 and Phase 3 data, covered separately on this site, has shown weight loss in a comparable double-digit percentage range over similar timeframes, though the two drugs were tested in different trial populations (MASH patients versus people with obesity) using different endpoints, which makes a precise apples-to-apples efficacy comparison unreliable from public data alone.
Safety Profiles
Both drugs, as GLP-1/glucagon dual agonists, share a safety profile broadly similar to other incretin-based drugs, with gastrointestinal side effects like nausea being commonly reported in early trials. Reported discontinuation rates due to adverse events in pemvidutide's IMPACT trial were low, 1.2% at the 1.8 mg dose versus 3.5% on placebo. Detailed comparative safety data between the two specific drugs isn't available since they haven't been studied together in a single trial.
The Bottom Line
Survodutide and pemvidutide share a receptor mechanism but are running different races: survodutide toward an obesity indication in a more advanced Phase 3 program, pemvidutide toward a liver-disease indication earlier in development, with an alcohol use disorder program alongside it. Neither is approved or available by prescription, and choosing between them isn't a decision patients or physicians can currently make, since neither has reached the market. Anyone interested in this drug class for an approved use today should discuss FDA-approved options with a physician rather than trying to substitute an investigational drug for one.